Communiqués BioNTech SE BOERSE MUENCHEN

Actions

22UA

US09075V1026

Temps réel BOERSE MUENCHEN Autres places de cotation 18:11:02 03/06/2024			Varia. 5j.	Varia. 1 janv.
94,05 ^EUR	+1,51%		+3,87%	-2,62%

17:25	Les actions européennes échangées aux Etats-Unis et les American Depositary Receipts chutent dans les échanges de lundi	MT
31/05	Les actions européennes négociées aux États-Unis sous forme de certificats américains d'actions étrangères (ADR) augmentent vendredi, mais pourraient terminer la semaine en baisse.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	01/06	AQ
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	01/06	GL
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP	31/05	AQ
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns	30/05	AQ
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 17 May 2024)	30/05	PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 1 June 2022)	30/05	PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 22 June 2021)	30/05	PU
BioNTech : Publication of the resolutions and system for the remuneration of the members of the management Board (resolution of the AGM on 17 May 2024)	30/05	PU
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem	29/05	GL
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership	27/05	PR
BioNTech : to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas	22/05	PU
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024	21/05	GL
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024	17/05	GL
BioNTech : Corporate Presentation	13/05	PU
BioNTech : First Quarter 2024 Financial Report	06/05	PU
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update	06/05	GL
Moderna Litigation Against BioNTech And Pfizer Stayed Pending IPR	06/05	AQ
GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech For Infringing MRNA Vaccine Patents	03/05	AQ
BioNTech : Joint report of the Management Board of BioNTech SE and the management of BioNTech Collaborations GmbH on the domination and profit and loss transfer agreement pursuant to Section 293a AktG	03/05	PU
BioNTech : Report of the Management Board on Agenda Items 12 and 13 lit. c) and d)	03/05	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

BIONTECH : Un raté est un raté

Le 21 mars 2024 à 14:27

BioNTech SE : Valorisation à la casse

Le 21 mars 2024 à 09:28